{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-023065","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.228719+00:00","generated_at":"2026-06-02T01:38:24.871919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Delcath Systems Q1 2024 revenue jumps to $3.1M; raises center activation target to 20 by year-end","bullets":["Revenue $3.1M, up from $0.6M YoY, driven by HEPZATO KIT sales of $2.0M and CHEMOSAT of $1.1M.","Raised $7.0M in private placement; cash and investments total $27.2M at quarter end.","Appointed Dr. Martha S. Rook as COO; expanded center activation goal to 20 by end of 2024.","Received permanent J-code (J9248) and pass-through payment for HEPZATO KIT from CMS effective April 1.","SG&A rose to $8.8M from $4.2M due to commercial launch; R&D decreased to $3.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-023065","json":"https://secwatch.observer/filing/0001628280-24-023065.json","markdown":"https://secwatch.observer/filing/0001628280-24-023065.md","text":"https://secwatch.observer/filing/0001628280-24-023065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828024023065/0001628280-24-023065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828024023065/dcth-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:38:24.871919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2ab7516748dacf72d1055873453f936039d93c1","claim":"DELCATH SYSTEMS, INC. reported the first quarter ended March 31, 2024 results: revenue $3.1 million.","evidence_excerpt":"Total revenue for the quarter ended March 31, 2024 was $3.1 million compared to $0.6 million for the same period in the prior year from our sales of HEPZATO in the U.S. and CHEMOSAT in Europe.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872912/000162828024023065/0001628280-24-023065-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}